title: Inhibitory effects of Ficus erecta leaves on osteoporotic factors in vitro.
abstract: Osteoporosis is recognized as a major concern among menopausal women and the elderly. When estrogen is reduced in the body, local factors such as IL-1beta, IL-6 and PGE2, which are known to be related to bone resorption, are increased and promote osteoclastogenesis, which is responsible for bone resorption and results in the clinical disorder osteoporosis. In this study, we investigated the anti-osteoporotic activity of Ficus erecta. MG-63 cells were stimulated with IL-1beta (10 ng/mL) to induce osteoporotic factors (IL-6, COX-2 and PGE2) and RAW 264.7 cells were stimulated with RANKL (100 ng/mL) to induce their differentiation into osteoclasts. We found F. erecta fractions decreased the mRNA expression of IL-6 and COX-2, and protein levels of COX-2 and PGE2 production. Among sequential solvent fractions, hexane and EtOAc fractions decreased differentiation into osteoclasts of RAW 264.7 cells. These results suggest that F. erecta may have significant effects on osteoporotic factors and may be provided as a possible anti-osteoporotic therapeutic plant.
authors.affiliation: Department of Pharmacology, College of Medicine, Cheju National University, Jeju 690-756, Korea.
authors.forename: Weon Jong
authors.initials: WJ
authors.lastname: Yoon
authors.forename: Hye Ja
authors.initials: HJ
authors.lastname: Lee
authors.forename: Gyeoung Jin
authors.initials: GJ
authors.lastname: Kang
authors.forename: Hee Kyoung
authors.initials: HK
authors.lastname: Kang
authors.forename: Eun Sook
authors.initials: ES
authors.lastname: Yoo
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000633:toxicity; D016723:Bone Remodeling / Q000187:drug effects*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D030681:Ficus; D006801:Humans; D053583:Interleukin-1beta / Q000494:pharmacology; D015850:Interleukin-6 / Q000378:metabolism; D008264:Macrophages / Q000166:cytology / Q000187:drug effects*; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*; D010024:Osteoporosis / Q000503:physiopathology; D010936:Plant Extracts / Q000494:pharmacology; D018515:Plant Leaves; D053245:RANK Ligand / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012997:Solvents / Q000737:chemistry; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; C508600:IL6 protein, human; D053583:Interleukin-1beta; D015850:Interleukin-6; D008565:Membrane Proteins; D010936:Plant Extracts; D053245:RANK Ligand; D012333:RNA, Messenger; D012997:Solvents; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D015232:Dinoprostone